{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T17:22:25Z","timestamp":1775841745101,"version":"3.50.1"},"reference-count":20,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,6,3]],"date-time":"2019-06-03T00:00:00Z","timestamp":1559520000000},"content-version":"vor","delay-in-days":579,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Hepatology"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.5604\/01.3001.0010.5279","type":"journal-article","created":{"date-parts":[[2017,10,17]],"date-time":"2017-10-17T03:07:39Z","timestamp":1508209659000},"page":"888-892","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Clinical Analysis of Polyethylene Glycol Interferon-\u03b1 Treatment in 155 Hepatitis B e Antigen (HBeAg)-Positive Chronic Hepatitis B (CHB) Patients"],"prefix":"10.1016","volume":"16","author":[{"given":"Xin","family":"Luo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji-Xian","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen-Jun","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li-Hong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.5604\/01.3001.0010.5279_bib0010","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1002\/hep.20110","article-title":"Chronic hepatitis B: update of recommendations","volume":"39","author":"Lok","year":"2004","journal-title":"Hepatology"},{"issue":"9401","key":"10.5604\/01.3001.0010.5279_bib0015","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1016\/S0140-6736(03)15108-2","article-title":"Viral hepatitis B","volume":"362","author":"Lai","year":"2003","journal-title":"Lancet"},{"issue":"4","key":"10.5604\/01.3001.0010.5279_bib0020","first-page":"500","article-title":"The research progress of chronic hepatitis B","volume":"6","author":"Chen","year":"2011","journal-title":"China Medicine"},{"issue":"12","key":"10.5604\/01.3001.0010.5279_bib0025","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1111\/j.1365-2893.2009.01254.x","article-title":"Hepatitis B virus genotype and basal core promoter\/precore mutations are associated with hepatitis B-related acute-on-chronic liver failure without pre-existing liver cirrhosis","volume":"17","author":"Ren","year":"2010","journal-title":"J Viral Hepa-tology"},{"issue":"3","key":"10.5604\/01.3001.0010.5279_bib0030","first-page":"205","article-title":"The study of the consequence about \u03b1-interferon and Hepatitis B virus genotype of B and C on the treatment of chronic Hepatitis B","volume":"41","author":"Jiang ZW and Liu","year":"2013","journal-title":"Modern Medicine"},{"issue":"7","key":"10.5604\/01.3001.0010.5279_bib0035","first-page":"1767","article-title":"The study of the consequence about acupoint injection α-interferon on the treatment of chronic Hepatitis B","volume":"2","author":"Zhang","year":"2012","journal-title":"China\u2019s health care nutrition"},{"issue":"4","key":"10.5604\/01.3001.0010.5279_bib0040","first-page":"315","article-title":"The expression of peripheral blood mononuclear cells TLR4 and the change of serum type Th1\/Th2 cytokines on the \u03b1-interferon treatment of chronic Hepatitis B","volume":"15","author":"Li","year":"2012","journal-title":"Practical Hepatology"},{"issue":"1","key":"10.5604\/01.3001.0010.5279_bib0045","first-page":"13","article-title":"The guideline of prevention and treatment of chronic hepatitis B (2010)","volume":"19","year":"2011","journal-title":"Chin J Hepatol"},{"key":"10.5604\/01.3001.0010.5279_bib0050","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1053\/gast.2001.24839","article-title":"Management of hepatitis B: 2000-summary of a workshop","volume":"120","author":"Lok","year":"2001","journal-title":"Gastroenterology"},{"issue":"7","key":"10.5604\/01.3001.0010.5279_bib0055","first-page":"890","article-title":"The antiviral mechanism and effect of interferon on viral hepatitis","volume":"22","author":"Li","year":"2005","journal-title":"China Public Health"},{"issue":"10","key":"10.5604\/01.3001.0010.5279_bib0060","first-page":"1276","article-title":"The advance of the anti-hepatitis virus mechanisms about \u03b1-interferon and peg-inter-feron","volume":"14","author":"Xu","year":"2008","journal-title":"Chinese Pharmacological Bulletin"},{"issue":"3","key":"10.5604\/01.3001.0010.5279_bib0065","first-page":"232","article-title":"The curative effect analysis of partial response of nucleoside analogues on the treatment of chronic hepatitis B to continue with the alpha interferon","volume":"16","author":"Lin","year":"2013","journal-title":"Practical Hepatology"},{"issue":"2","key":"10.5604\/01.3001.0010.5279_bib0070","first-page":"53","article-title":"Analysis of the adverse drug reactions of \u03b1-inter-feron on the treatment of chronic hepatitis B","volume":"6","author":"You","year":"2013","journal-title":"Clinical rational Drug Use"},{"issue":"10","key":"10.5604\/01.3001.0010.5279_bib0075","first-page":"267","article-title":"The clinical observation of Peg-interferon \u03b1-2 a180 \u03bcg combined with adefovir on the treatment of chronic hepatitis B","volume":"12","author":"Li","year":"2012","journal-title":"The latest medical information abstract"},{"issue":"5","key":"10.5604\/01.3001.0010.5279_bib0080","first-page":"640","article-title":"The clinical observation of peg-interferon compared with conventional interferon on treatment of 60 cases of chronic hepatitis B","volume":"19","author":"Shi","year":"2015","journal-title":"Public Medical Forum"},{"issue":"34","key":"10.5604\/01.3001.0010.5279_bib0085","first-page":"126","article-title":"The research of the side effects and clinical significance of alpha interferon on the treatment of chronic hepatitis B","volume":"7","author":"Wang","year":"2014","journal-title":"Chin J Biochem Pharm"},{"issue":"7","key":"10.5604\/01.3001.0010.5279_bib0090","first-page":"94","article-title":"The effect comparison of Peg-in-terferon with conventional interferon on treatment of chronic hepatitis B","volume":"22","author":"Chen","year":"2013","journal-title":"Clinical Medical"},{"key":"10.5604\/01.3001.0010.5279_bib0095","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1046\/j.1365-2893.2003.00450.x","article-title":"Peginterferon \u03b1-2a(40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B","volume":"10","author":"Cooksley","year":"2003","journal-title":"J Viral Hepatitis"},{"key":"10.5604\/01.3001.0010.5279_bib0100","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1177\/135965350801300406","article-title":"Treatment of patients with chronic hepatitis B who have failed previous antiviral treatment with pegylat-ed interferon alpha-2a","volume":"13","author":"Chan","year":"2008","journal-title":"Antiviral therapy"},{"key":"10.5604\/01.3001.0010.5279_bib0105","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1111\/j.1872-034X.2009.00592.x","article-title":"Comparison between quantitative hepatitis B surface antigen, hepatitis B e-antigen and hepatitis B virus DNA levels for predicting virological response to pegylated interferon \u03b1-2b therapy in hepatitis B e-antigen-positive chronic hepatitis B","volume":"40","author":"Tangkijvanich","year":"2010","journal-title":"Hepatology Research"}],"container-title":["Annals of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1665268119304557?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1665268119304557?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T10:34:57Z","timestamp":1761647697000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1665268119304557"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":20,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["S1665268119304557"],"URL":"https:\/\/doi.org\/10.5604\/01.3001.0010.5279","relation":{},"ISSN":["1665-2681"],"issn-type":[{"value":"1665-2681","type":"print"}],"subject":[],"published":{"date-parts":[[2017,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical Analysis of Polyethylene Glycol Interferon-\u03b1 Treatment in 155 Hepatitis B e Antigen (HBeAg)-Positive Chronic Hepatitis B (CHB) Patients","name":"articletitle","label":"Article Title"},{"value":"Annals of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.5604\/01.3001.0010.5279","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2017 Fundaci\u00f3n Cl\u00ednica M\u00e9dica Sur, A.C. Published by Elsevier Espa\u00f1a, S.L.","name":"copyright","label":"Copyright"}]}}